This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pannett, A. A. J. Articles by Thakker, R. V. Search for Related Content PubMed PubMed Citation Articles by Pannett, A. A. J. Articles by Thakker, R. V.

Somatic Mutations in MEN Type 1 Tumors, Consistent with the Knudson "Two-Hit" Hypothesis

Molecular Endocrinology Group, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, United Kingdom OX3 9DU

Address all correspondence and requests for reprints to Prof. R. V. Thakker, M.D., Molecular Endocrinology Group, Nuffield Department of Medicine, Level 7, University of Oxford, John Radcliffe Hospital, Headington, Oxford, United Kingdom OX3 9DU.

Abstract

MEN type 1 is an autosomal dominant disorder characterized by the combined occurrence of tumors of the parathyroids, anterior pituitary, and pancreatic islet cells. The MEN1 gene, which is located on chromosome 11q13, consists of 10 exons and encodes a 610-amino acid protein named MENIN. The observation of LOH involving 11q13 in MEN type 1 tumors and the inactivating germline mutations found in patients suggest that the MEN1 gene acts as a tumor suppressor, in keeping with the "two-hit" model of hereditary cancer. The second hit in MEN type 1 tumors typically involves large chromosomal deletions that include 11q13. However, this only represents one mechanism by which the second hit may occur, and the other mechanisms, such as intragenic deletions or point mutations that inactivate the gene, have not been reported in MEN type 1 tumors. We have therefore undertaken studies to search for such mutations in six MEN type 1 tumors (four parathyroid tumors, one insulinoma, and one lipoma) that did not have LOH at 11q13 as assessed using the flanking markers D11S480, D11S1883 and PYGM centromerically and D11S449 and D11S913 telomerically. This revealed four somatic mutations, which consisted of two missense mutations and two frameshift mutations in two parathyroid tumors, one insulinoma, and one lipoma. Thus, our results, which represent the first small intragenic somatic mutations reported in MEN type 1 tumors, provide further evidence that the role of the MEN1 gene is consistent with that of a tumor suppressor gene, as postulated by Knudson’s "two-hit" hypothesis.

This article has been cited by other articles:

				P. S. H. Soon, K. L. McDonald, B. G. Robinson, and S. B. Sidhu Molecular Markers and the Pathogenesis of Adrenocortical Cancer Oncologist, May 1, 2008; 13(5): 548 - 561. [Abstract] [Full Text] [PDF]

				O Vierimaa, T M L Ebeling, S Kytola, R Bloigu, E Eloranta, J Salmi, E Korpi-Hyovalti, L Niskanen, A Orvola, E Elovaara, et al. Multiple endocrine neoplasia type 1 in Northern Finland; clinical features and genotype phenotype correlation Eur. J. Endocrinol., September 1, 2007; 157(3): 285 - 294. [Abstract] [Full Text] [PDF]

				F Cetani, E Pardi, E Ambrogini, P Viacava, S Borsari, M Lemmi, L Cianferotti, P Miccoli, A Pinchera, A Arnold, et al. Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation Endocr. Relat. Cancer, June 1, 2007; 14(2): 493 - 499. [Abstract] [Full Text] [PDF]

				D M Pritchard Pathogenesis of gastrinomas associated with multiple endocrine neoplasia type 1 Gut, May 1, 2007; 56(5): 606 - 607. [Full Text] [PDF]

				M Anlauf, A Perren, T Henopp, T Rudolf, N Garbrecht, A Schmitt, A Raffel, O Gimm, E Weihe, W T Knoefel, et al. Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions Gut, May 1, 2007; 56(5): 637 - 644. [Abstract] [Full Text] [PDF]

				A. Perren, M. Anlauf, T. Henopp, T. Rudolph, A. Schmitt, A. Raffel, O. Gimm, E. Weihe, W. T. Knoefel, H. Dralle, et al. Multiple Endocrine Neoplasia Type 1 (MEN1): Loss of One MEN1 Allele in Tumors and Monohormonal Endocrine Cell Clusters But Not in Islet Hyperplasia of the Pancreas J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1118 - 1128. [Abstract] [Full Text] [PDF]

				M. Crepin, P. Pigny, F. Escande, C. C. Bauters, A. Calender, S. Lefevre, M.-P. Buisine, N. Porchet, and M.-F. Odou Evaluation of denaturing high performance liquid chromatography for the mutational analysis of the MEN1 gene. J. Mol. Endocrinol., April 1, 2006; 36(2): 369 - 376. [Abstract] [Full Text] [PDF]

				S. J. Marx and W. F. Simonds Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes Endocr. Rev., August 1, 2005; 26(5): 615 - 661. [Abstract] [Full Text] [PDF]

				K J Bradley, B M Cavaco, M R Bowl, B Harding, A Young, and R V Thakker Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated primary hyperparathyroidism J. Med. Genet., August 1, 2005; 42(8): e51 - e51. [Abstract] [Full Text] [PDF]

				B. M. Cavaco, L. Guerra, K. J. Bradley, D. Carvalho, B. Harding, A. Oliveira, M.-A. Santos, L. G. Sobrinho, R. V. Thakker, and V. Leite Hyperparathyroidism-Jaw Tumor Syndrome in Roma Families from Portugal Is Due to a Founder Mutation of the HRPT2 Gene J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1747 - 1752. [Abstract] [Full Text] [PDF]